Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PROSTVAC-F-TRICOM | PROSTVAC-F-TRICOM is a cancer vaccine consisting of a recombinant fowlpox virus encoding PSA and TRICOM (a combination of B7.1, ICAM-1, and LFA-3), which induces antitumor immune response against PSA-positive tumors (PMID: 16390546). | |||
PROSTVAC-V-TRICOM | PROSTVAC-V-TRICOM is a cancer vaccine consisting of a recombinant vaccinia virus encoding PSA and TRICOM (a combination of B7.1, ICAM-1, and LFA-3) which induces antitumor immune response against PSA-positive tumors (PMID: 16390546). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02506114 | Phase II | PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM Ipilimumab Ipilimumab + PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM | Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer | Terminated | USA | 0 |